首页 > 市场调查报告书 > 製药

孤儿药

市场调查报告书

商品编码

1469861

全球孤儿药市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

Global Orphan Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年04月01日 | 出版商:

Value Market Research | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球孤儿药市场需求预计将从 2023 年的 1,949.5 亿美元达到近 3,620.4 亿美元的市场规模，2024-2032 年研究期间复合年增长率为 7.12%。

孤儿药是一种为治疗影响少数人的罕见疾病或病症而生产的药物。由于患者群体有限以及药物开发和商业化的挑战，製药公司往往需要更多地关注这些疾病。这些药物，包括延长专利保护、税收抵免和加速审批流程，获得特殊的监管激励和市场独占权，以鼓励其成长。

市场动态

罕见疾病和病症的日益普及以及基因研究和诊断技术的进步推动了对针对特定基因突变或罕见疾病的孤儿药的需求。此外，卫生当局授予的监管奖励措施和孤儿药称号，例如美国的《孤儿药法案》和其他国家的类似法规，鼓励製药公司投资于孤儿药的研发。此外，越来越多的罕见疾病患者倡导和支持团体正在提高人们的意识并倡导获得孤儿药，从而推动需求并促进市场成长。此外，生物技术和药物开发技术的进步，例如基因治疗、细胞疗法和精准医学方法，使得能够开发出具有更高疗效和安全性的创新孤儿药物疗法。

此外，孤儿药治疗的医疗保健支出和保险覆盖范围不断增加，加上个人化医疗和基于价值的医疗保健模式的日益接受，为孤儿药製造商创造了有利的市场条件。此外，製药公司、学术机构和研究组织之间的策略合作和伙伴关係促进创新并加速孤儿药的开发和商业化。然而，来自替代疗法的日益激烈的竞争和有限的患者使用可能会挑战未来几年孤儿药市场的成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球孤儿药市场的各个细分市场进行了包容性评估。孤儿药产业的成长和趋势为本研究提供了整体方法。

市场区隔

孤儿药市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助战略家确定相应产品或服务的目标人群以及即将到来的机会。

依疾病类型

肿瘤学
胃肠道
肺部
神经病学
血液学
心血管
代谢紊乱
内分泌科
传染性疾病
其他的

按指标

生物製剂
非生物

按配销通路

医院药房
专业药房
零售药局
其他的

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲孤儿药市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。孤儿药市场的主要参与者包括诺华公司、百时美施贵宝公司、新基公司、罗氏有限公司、辉瑞公司、赛诺菲公司、亚力兄製药公司、礼来公司、诺和製药公司Nordisk A/ S、阿斯特捷利康公司、卫材有限公司、第一三共有限公司、拜耳公司、葛兰素史克公司、默克公司、强生公司。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 9 章：孤儿药公司的竞争格局

孤儿药市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 10 章：公司简介

顶级公司市占率分析
市场集中度
Novartis AG

公司简介
公司收入
产品
最近的发展

Bristol-Myers Squibb Company

公司简介
公司收入
产品
最近的发展

Celgene Corporation

公司简介
公司收入
产品
最近的发展

F. Hoffmann-La Roche Ltd.

公司简介
公司收入
产品
最近的发展

Pfizer Inc.

公司简介
公司收入
产品
最近的发展

Sanofi SA

公司简介
公司收入
产品
最近的发展

Alexion Pharmaceuticals Inc.

公司简介
公司收入
产品
最近的发展

Eli Lilly And Company

公司简介
公司收入
产品
最近的发展

Novo Nordisk A/S

公司简介
公司收入
产品
最近的发展

AstraZeneca Plc

公司简介
公司收入
产品
最近的发展

Eisai Co. Ltd.

公司简介
公司收入
产品
最近的发展

Daiichi Sankyo Company Limited

公司简介
公司收入
产品
最近的发展

Bayer AG

公司简介
公司收入
产品
最近的发展

GlaxoSmithKline Plc

公司简介
公司收入
产品
最近的发展

Merck & Co. Inc.

公司简介
公司收入
产品
最近的发展

Johnson & Johnson

公司简介
公司收入
产品
最近的发展

註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR112114268

The global demand for Orphan Drugs Market is presumed to reach the market size of nearly USD 362.04 Billion by 2032 from USD 194.95 Billion in 2023 with a CAGR of 7.12% under the study period 2024 - 2032.

Orphan drugs are pharmaceutical medications created to treat rare diseases or conditions impacting a small number of individuals. Pharmaceutical companies often need to pay more attention to these diseases due to their limited patient populations and drug development and commercialization challenges. These drugs, including extended patent protection, tax credits, and accelerated approval processes, receive special regulatory incentives and market exclusivity to encourage their growth.

MARKET DYNAMICS

The increasing prevalence of rare diseases and disorders and advances in genetic research and diagnostic technologies drive the demand for orphan drugs targeting specific genetic mutations or rare conditions. Additionally, regulatory incentives and orphan drug designations granted by health authorities, such as the Orphan Drug Act in the United States and similar regulations in other countries, encourage pharmaceutical companies to invest in the research and development of orphan drugs. Furthermore, the growing patient advocacy and support groups for rare diseases are raising awareness and advocating for access to orphan drugs, driving demand and facilitating market growth. Moreover, advancements in biotechnology and drug development techniques, such as gene therapy, cell therapy, and precision medicine approaches, enable the development of innovative orphan drug therapies with improved efficacy and safety profiles.

Additionally, the increasing healthcare expenditure and insurance coverage for orphan drug treatments, combined with the growing acceptance of personalized medicine and value-based healthcare models, create favorable market conditions for orphan drug manufacturers. Furthermore, strategic collaborations and partnerships between pharmaceutical companies, academic institutions, and research organizations foster innovation and accelerate the development and commercialization of orphan drugs. However, increasing competition from alternative therapies and limited patient access may challenge the growth of the orphan drugs market in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of orphan drugs. The growth and trends of orphan drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the orphan drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Disease Type

Oncology
Gastrointestinal
Pulmonary
Neurology
Hematology
Cardiovascular
Metabolic Disorders
Endocrinology
Infectious Diseases
Others

By Indicator

Biologic
Non-Biologic

By Distribution Channel

Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Orphan Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Orphan Drugs market include Novartis AG, Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., Pfizer, Inc., Sanofi S.A., Alexion Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S, AstraZeneca plc, Eisai Co., Ltd., Daiichi Sankyo Company Limited, Bayer AG, GlaxoSmithKline plc, Merck & Co., Inc., Johnson & Johnson. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. ORPHAN DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Disease Type
- 3.7.2 Market Attractiveness Analysis By Indicator
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL ORPHAN DRUGS MARKET ANALYSIS BY DISEASE TYPE

5.1. Overview By Disease Type
5.2. Historical and Forecast Data
5.3. Analysis By Disease Type
5.4. Oncology Historic and Forecast Sales By Regions
5.5. Gastrointestinal Historic and Forecast Sales By Regions
5.6. Pulmonary Historic and Forecast Sales By Regions
5.7. Neurology Historic and Forecast Sales By Regions
5.8. Hematology Historic and Forecast Sales By Regions
5.9. Cardiovascular Historic and Forecast Sales By Regions
5.10. Metabolic Disorders Historic and Forecast Sales By Regions
5.11. Endocrinology Historic and Forecast Sales By Regions
5.12. Infectious Diseases Historic and Forecast Sales By Regions
5.13. Others Historic and Forecast Sales By Regions

6. GLOBAL ORPHAN DRUGS MARKET ANALYSIS BY INDICATOR

6.1. Overview By Indicator
6.2. Historical and Forecast Data
6.3. Analysis By Indicator
6.4. Biologic Historic and Forecast Sales By Regions
6.5. Non-biologic Historic and Forecast Sales By Regions

7. GLOBAL ORPHAN DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1. Overview By Distribution Channel
7.2. Historical and Forecast Data
7.3. Analysis By Distribution Channel
7.4. Hospital Pharmacies Historic and Forecast Sales By Regions
7.5. Specialty Pharmacies Historic and Forecast Sales By Regions
7.6. Retail Pharmacies Historic and Forecast Sales By Regions
7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL ORPHAN DRUGS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE ORPHAN DRUGS COMPANIES

9.1. Orphan Drugs Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF ORPHAN DRUGS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Novartis AG
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Bristol-Myers Squibb Company
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Celgene Corporation
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. F. Hoffmann-La Roche Ltd.
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Pfizer Inc.
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Sanofi S.A.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Alexion Pharmaceuticals Inc.
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Eli Lilly And Company
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Novo Nordisk A/S
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. AstraZeneca Plc
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. Eisai Co. Ltd.
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. Daiichi Sankyo Company Limited
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments
10.15. Bayer AG
- 10.15.1 Company Overview
- 10.15.2 Company Revenue
- 10.15.3 Products
- 10.15.4 Recent Developments
10.16. GlaxoSmithKline Plc
- 10.16.1 Company Overview
- 10.16.2 Company Revenue
- 10.16.3 Products
- 10.16.4 Recent Developments
10.17. Merck & Co. Inc.
- 10.17.1 Company Overview
- 10.17.2 Company Revenue
- 10.17.3 Products
- 10.17.4 Recent Developments
10.18. Johnson & Johnson
- 10.18.1 Company Overview
- 10.18.2 Company Revenue
- 10.18.3 Products
- 10.18.4 Recent Developments